nav markers

We envision a world where data empowers mental wellness.

To identify the link between biological markers and mental health conditions.

HONESTY & TRANSPARENCY. We will always act with honesty and transparency in our dealings with others.

RESPECT We will always have regard for the feelings, wishes and rights of others.

INTEGRITY We will always act having regard to the highest moral principles.

EXCELLENCE We will always strive in the pursuit of excellence.

our approach

High prevalence of major depression in US sleep clinics: the need for routine depression screening in sleep services

Silvia Daccò, PsyD, Daniela Caldirola, MD, PhD, Massimiliano Grassi, PsyD, Alessandra Alciati, MD, Giampaolo Perna, MD, PhD, Archie Defillo, MD
Published Online: April 1, 2023

Depression screening is not part of routine clinical practice in US sleep clinics. Our study aimed to report the prevalence of depression among individuals referred to US sleep clinics. According to our findings, approximately 21% of patients had depression, with about 4% reporting severe symptoms, 9% had frequent death and/or self-harming thoughts, and 61% were taking antidepressants. Our results highlighted a considerable risk of prevalent depression in sleep clinics and supported the limited existing data on this topic. Our study advocates for the need for routine depression screening in sleep services to reduce the detrimental consequences of a delayed depression diagnosis and the risk of a worse prognosis for both depression and sleep–wake disorders.

We take sleep physiology, subjects' sociodemographic and clinical characteristics, and we use AI to connect them and extract biomarkers that can map a subjects’ mental health status.


Identifies the four important sleep stages of a subject and aids in the determination of sleep architecture features and mapping of autonomic function throughout the sleep stages.


MEB-001 will be a Software Medical Device that uses artificial intelligence to map a subjects' mental health.

our team
Dr. Archie

Dr. Archie Defillo
Chief Medical Officer

Kai Sun
Chief Operating Officer


Dr. Massimiliano Grassi
Head of Artificial Intelligence

David Trimboli
Non-executive Chairman

Mr Trimboli is an experienced global investor with experience in commodities financing and trading. He has undertaken investments activities and hold diverse interests in commodities, industrial minerals, real estate and technology and mental health in Australia and internationally. Mr Trimboli is the founder of Seefeld Investments with offices in London, Zug and Perth. He has formerly a long serving senior coal trader at the world’s largest commodities trading group, Glencore International AG and was a key member of the Glencore team when the group successfully completed its IPO in London and Hong Kong. He currently holds a Managing Director position in Seefeld Investments Pty Ltd, Non-Executive Chairman in Audeara Limited (ASX: AUA) and Non-Executive Director positions in the following Companies Quantum Graphite Limited (ASX: QGL), TradeMutt, Yumm Confectionar, The Reading Switch, Carecircle and Greater Outcomes, all being companies in revenue generating businesses with developed management teams and on pathways to profitability.
Dr. Tom Young
Non-executive Director

Dr. Tom Young is a board-certified family physician with more than 35 years of medical experience. Tom is a recognized thought leader in consumer-directed healthcare and population health management and can often be found speaking at behavioral health industry events. Tom lives in Boise, ID, with his wife.
Chris Ntoumenopoulos
Non-executive Director

Mr Ntoumenopoulos holds the position as a Director at Tryp Therapeutics. He has a background as the former Managing Director at 21 Corporate, an Australian corporate advisory firm. He is also a seasoned entrepreneur on the lookout for innovative and groundbreaking technologies and businesses. With over 20 years of experience in the financial sector, Mr Ntoumenopoulos has a strong track record in raising capital and providing corporate advice. He was also a founding director of ResApp Health, which Pfizer and Race Oncology later acquired. Mr Ntoumenopoulos holds a Bachelor of Commerce degree from the University of Western Australia, focusing on Money and Banking, Investment Finance, and Electronic Commerce.

Contact Us

Minneapolis, Minnesota | 8696 Eagle Creek Circle | Savage, MN 55378

Perth, Western Australia | 647 Beaufort Street | Mount Lawley WA 6050